Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Khaldoun Debian

Gastroenterology Tustin, CA Medical Doctor

NPI 1932168796 CMS profile 178100

17400 Irvine Blvd Ste F, Tustin, CA 92780

Open in the dashboard

General payments

$5,641

304 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$195,315 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Khaldoun Debian of Tustin, CA is reported in the CMS Open Payments database as having received $5,641 across 304 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $195,315 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 69th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,187 49
2024 General $1,021 55
2023 General $794 52
2022 General $935 49
2021 General $984 58
2020 General $547 30
2019 General $173 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Khaldoun Debian
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Khaldoun Debian were reported at $1,187. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Khaldoun Debian Gastroenterology median Middle half National median
2019 $173 $417 $126–$1,100 $163
2020 $547 $224 $74–$624 $114
2021 $984 $352 $106–$1,054 $132
2022 $935 $448 $129–$1,270 $149
2023 $794 $533 $150–$1,390 $160
2024 $1,021 $605 $160–$1,606 $164
2025 $1,187 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $1,196 73 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $919 52 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $746 54 payments
  4. AbbVie, Inc. $650 33 payments
  5. Pfizer Inc. $301 11 payments
  6. Ardelyx, Inc. $256 11 payments
  7. Nestle HealthCare Nutrition Inc. $242 10 payments
  8. Gilead Sciences, Inc. $227 10 payments
  9. Genzyme Corporation $131 5 payments
  10. RedHill Biopharma Inc. $103 6 payments
  11. Other $870 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,432 299 payments
  2. Education $128 4 payments
  3. Debt forgiveness $81 1 payment
Products named General payments · program years 2019–2025
  1. STELARA $968 60 payments
  2. XIFAXAN $673 33 payments
  3. TREMFYA $503 30 payments
  4. ENTYVIO $470 38 payments
  5. SIMPONI ARIA $464 37 payments
  6. SIMPONI $464 37 payments
  7. LINZESS $389 22 payments
  8. TRULANCE $263 20 payments
  9. VIBERZI $263 14 payments
  10. IBSRELA $256 11 payments
  11. Other $2,826 140 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

829

Median for Gastroenterology: 569

Drug cost

$51,640

Median for Gastroenterology: $104,976

Branded share of claims

16.9%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 25 $19,086
Trulance Plecanatide Brand 16 $11,964
Mesalamine Generic 29 $5,200
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 83 $4,388
Famotidine Generic 201 $2,860
Dexlansoprazole Dr Dexlansoprazole Brand 16 $2,826
Pantoprazole Sodium Generic 177 $1,433
Lubiprostone Generic 13 $1,421
Dicyclomine Hcl Generic 47 $924
Omeprazole Generic 114 $794

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$33,673

Medicare's payments for the services billed

Medicare patients

150

Average age 73

Services billed

351

83 women, 67 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 37%
Ischemic heart disease 33%
Chronic kidney disease 30%
Depression 24%
Osteoporosis 24%
Heart failure 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $152
$152 — —
TREMFYA
  • Janssen Biotech, Inc. $74
$74 — —
STELARA
  • Janssen Biotech, Inc. $68
$68 — —
DUPIXENT
  • GENZYME CORPORATION $47
  • Regeneron Healthcare Solutions, Inc. $14
$61 — —
TRULANCE
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $52
$52 16 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

304 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record